Navigation Links
BioMarCare Technologies Ltd. Granted Access to Archived Samples in the Hadassah Medical Center
Date:11/7/2011

NEW YORK, Nov. 7, 2011 /PRNewswire/ -- Hadasit Bio-Holdings, Ltd. - (OTCBB: HADSY), a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, and its subsidiary, BioMarCare Technologies Ltd. ("BioMarCare") announced that the Hospital's Ethics Committee has approved the use of up to 400 tissue biopsy samples in a retrospective clinical study.

BioMarCare will use these samples in a study designed to develop a diagnostic test for patients with metastatic stage colorectal cancer eligible for anti-EGFR treatment. The Company will characterize the expression profile of specific biomarkers in respect to the therapeutic response status of anti-EGFR therapy responders versus non-responders. The new test may enable physicians to detect non-responder patients prior to treatment with anti-EGFR therapy and then select a more effective treatment method.

This diagnostic tool may provide physicians with additional insight and assistance in providing more efficient and personalized treatment options. The study, expected to begin later this year, is supported by the prestigious US-Israeli Binational Industrial Research and Development (BIRD) Foundation and is part of a collaboration between BioMarCare and Ariadne Inc. (FLA). The companies will jointly develop the diagnostic test, based on a panel of protein biomarkers, directly impacting the personal care of patients with metastatic stage colorectal cancer. Colorectal cancer is the third most common malignant disease in the world, with more than one million new cases discovered annually and more than 30% diagnosed in the metastatic stage.

"The accessibility to Hadassah Medical Center's staff and resources, available to us primarily through Hadasit Bio-Holdings, significantly accelerated the development of our products and research programs," stated Dana Cohen, BioMarCare's CEO.  "This additional approval will further strengthen our ties with the Oncology center as well as the Department of Pathology. Meanwhile, the company anticipates opening a second clinical trial site in another hospital and the BIRD grant will supplement Hadasit Bio-Holding's investments in BioMarCare to ensure this happens."

In addition to this important project, BioMarCare is also in the process of developing diagnostic tools for colon cancer and breast cancer that are based on a simple blood or biopsy test. These tests utilize proprietary biomarkers, licensed from the Hadassah Medical Organization's technology transfer company -- Hadasit, and have shown high sensitivity even at early stages of the disease.

The aforementioned BIRD grant is one of only nine competitive grants approved for Israeli American collaborations in 2011 and is awarded to Israeli American collaborations in various fields, not only medical. The grant will be matched by company funds and will be repaid through royalty payments from the developed product. BioMarCare and Ariadne Inc. are currently finalizing their collaboration agreement and will then finalize an agreement with the BIRD Foundation, as required by the fund.

About Hadasit Bio-Holdings

Hadasit Bio-Holdings Ltd., established in 2006, is the publicly traded subsidiary of Hadasit Ltd. - the technology transfer company of the Hadassah University Hospital, Israel's foremost medical research center.  The Company was established for the purpose of promoting and commercializing the intellectual property and R&D capabilities generated by Hadassah.

HADSY is the domestically traded ADR of Hadasit Bio-Holdings, a public investment vehicle representing a portfolio of biotech companies, all based on inventions developed at Hadassah.  

Hadasit Bio-Holdings focuses on advancing companies that are past successful preclinical trials and close to completion of Phase I/II clinical trials. The portfolio companies develop drugs with blockbuster potential (markets that are worth over a billion dollars) and operate in the fields of cancer, inflammatory diseases and tissue regeneration using stem cells - areas in which the Hadassah Hospital has extensive knowledge and recognition as a global leader.

For more information please visit: www.hbl.co.il.

Investor Contact
KCSA Strategic Communications
Jeff Corbin / Rob Fink
jcorbin@kcsa.com / rfink@kcsa.com
(212) 896-1206


'/>"/>
SOURCE Hadasit Bio-Holdings, Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMarCare Technologies Ltd. Receives a $900k Grant for a Joint Project with Ariadne Inc.
2. Medisafe 1 Technologies Pre-pays Additional 2 Convertible Promissory Notes Due in Full to Avoid Dilution to Shareholders
3. Filtrona Porous Technologies to Introduce New Hydrophilic Foam Products for Advanced Wound Care at the MEDICA / COMPAMED Trade Fair
4. Micell Technologies Announces Presentation of Clinical Data at TCT 2011
5. China Medical Technologies to Announce Results for the Second Fiscal Quarter Ended September 30, 2011 on November 18, 2011
6. AquaLiv Technologies Subsidiary AquaLiv, Inc. Discusses Registration In Kenya Concerning Its HIV/AIDS Treatment
7. The Future of GPCRs in Drug Discovery: Novel technologies, leading companies, and opportunities for target expansion
8. Connectyx Technologies to Host Teleconference on Third Quarter Financial Results on Tuesday November 15, 2011
9. Life Technologies Signs Agreement with GlaxoSmithKline Biologicals S.A., Seeking Expanded Use of Platform Technologies into Companion Diagnostics
10. China Medical Technologies Recently Received Approximately 2,200,000 of its ADSs from Two Banks which Borrowed the ADSs in Connection With the Issuance of the Companys Convertible Notes in August 2008
11. Hologic to Host Special Tomosynthesis Symposium and Feature the Latest in Womens Health Technologies at the Journees Francaises de Radiologie (JFR)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2017)... , Sept. 5, 2017 Oramed Pharmaceuticals Inc. ... ), a clinical-stage pharmaceutical company focused on the development ... has successfully concluded its meeting with the U.S. Food ... oral insulin formulation. ... the regulatory pathway for submission of ORMD-0801, would be ...
(Date:9/1/2017)...  Bayer will present the latest research from across its ... (ESMO) 2017 Congress, September 8-12 in Madrid, Spain ... clinical data on Bayer,s marketed portfolio and late-stage compounds as ... "We value the opportunity to ... at ESMO," said Carsten Brunn , Head of Pharmaceuticals, ...
(Date:8/29/2017)... 29, 2017 In a move that promises ... compliance for veterinary practices of all sizes, Cubex LLC ... that makes TITAN,s expertise in physical security, drug diversion ... clients nationally. ... controlled substances is at risk today," said TITAN founder ...
Breaking Medicine Technology:
(Date:9/19/2017)... ... September 19, 2017 , ... Trusted debt-reduction firm CreditAssociates, LLC has announced two ... in excess of $835 million in resolved debt for its clients. , Credit card ... of the categories of debt settled by the company. With more than a decade ...
(Date:9/19/2017)... ... September 19, 2017 , ... Arizona-based ... as the President of its HealthBI division. McFarland will grow the organization’s ... , “Scott is a utility player who balances his day as a ...
(Date:9/19/2017)... Hill, CT (PRWEB) , ... September 19, 2017 ... ... support, today announced the winners of the Entrepreneur Innovation Awards (EIA), held this ... all of whom are Connecticut-based companies and entrepreneurs, presented their innovative project ideas ...
(Date:9/19/2017)... ... September 19, 2017 , ... MelaKids, a Laredo-based company, has introduced a new ... we’re born, Nature gives us a full supply of melanin – in the back ... this natural glare-reducing pigment; however, around the age of thirty, we develop a yellow-brown ...
(Date:9/19/2017)... ... September 19, 2017 , ... Presenting its annual ... (SPBA) hosted “Expanding Your Success” with an educational emphasis. , The three-day ... best practices for third party administrators (TPAs) related to health plan management and ...
Breaking Medicine News(10 mins):